Skip to main content

Table 1 The therapeutic effects of hAMSCs on patients’ GCs with premature ovarian failure [68]

From: Human mesenchymal stem cell treatment of premature ovarian failure: new challenges and opportunities

  DOR (n = 29) POF (n = 36)
Control hAMSCs P value Control hAMSCs P value
No. of AMH cell 22% 83% < 0.01 4.5% 45% < 0.01
No. of FSHR cell 41% 84% < 0.01 17% 51% < 0.01
No. Of FOXL2 cell 34% 88% < 0.01 19% 70% < 0.01
No. of CYP19A1 cell 45% 92% < 0.01 34% 81% < 0.01